ArticleFrontiers in endocrinology2026
Cushing's syndrome and early growth hormone hypersecretion in a child with Carney complex: a case report.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Carney complex (CNC) is a rare autosomal dominant syndrome characterized by multiple endocrine and non-endocrine tumors. In childhood, Cushing's syndrome due to primary pigmented nodular adrenocortical disease (PPNAD) may occur, while growth hormone (GH) hypersecretion before puberty is exceptionally rare. Case presentation: A 5-year-old girl presented with rapid weight gain, facial changes, hypertension, hypokalemic alkalosis, and kidney stones. Biochemical evaluation confirmed ACTH-independent Cushing's syndrome, and abdominal magnetic resonance imaging (MRI) revealed bilateral adrenal nodules consistent with PPNAD. Family history of endocrine tumors and cardiac myxomas suggested CNC, subsequently confirmed by genetic testing showing a mutation of the PRKAR1A gene in both the patient and her father. Bilateral adrenalectomy resolved hypercortisolism. At 8.6 years, the patient showed an accelerated growth velocity (+2.48 SDS) with elevated IGF-1 levels and lack of GH suppression during an oral glucose tolerance testing, despite a normal pituitary MRI. She remained asymptomatic apart from growth acceleration, which was carefully monitored during follow-up. Over 18 months accelerated growth persisted with pubertal progression, but IGF-1 levels eventually normalized and brain MRI remained stable; therefore, treatment for GH excess was deferred. Conclusions: This case highlights the importance of considering CNC in pediatric ACTH-independent Cushing's syndrome and underlines the role of genetic testing. It also demonstrates that GH hypersecretion may emerge earlier than current screening recommendations, underscoring the need for surveillance starting at the onset of puberty.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.